Focus:

Article ID: 695138

Newly published report in Nature Reviews Drug Discovery that provides a comprehensive, independent analysis of the global landscape of cancer cell therapies, including all agents from preclinical to post-market stages.

Article ID: 695072

Health care providers, community members, and researchers from across New Jersey came together at the ‘Conference for Change’ event, hosted by the New Jersey Primary Care Association and sponsored by ScreenNJ to address the need to improve screening rates for colorectal and lung cancers.

Article ID: 695070

A new study in JNCCN finds that, contrary to screening recommendations, mammography rates decline over time as women get further out from their breast cancer diagnosis; African-American women in particular were less likely to receive the recommended amount of screening.

Article ID: 695068

Longer days means more exposure to the sun and harmful UV rays. A Rutgers Cancer Institute of New Jersey expert shares some tips on how to keep your skin safe this season and all year long.

Article ID: 694921

A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II or III colorectal cancer (CRC). Published in the Journal of the American Medical Association, the study is the largest of surveillance intensity in CRC ever conducted.

Article ID: 694872

University of Colorado Cancer Center study shows that stereotactic body radiation (SBRT) may be better against anaplastic thyroid cancer, and with fewer side effects.

Article ID: 694803

An analysis of lymph node dissection in non-metastatic renal cell carcinoma indicates the procedure is often performed for stage 1 disease and shows no overall survival benefit. Investigators from Rutgers Cancer Institute of New Jersey presented the work at the Annual Meeting of the American Urological Association.

Article ID: 694760

UC San Diego researchers have developed a test that can screen for pancreatic cancer in just a drop of blood. The test, which is at the proof-of-concept stage, provides results in under an hour. It's simple: apply a drop of blood on a small electronic chip, turn the current on, wait several minutes, add fluorescent labels and look at the results under a microscope. If a blood sample tests positive for pancreatic cancer, bright fluorescent circles will appear.

Article ID: 694748

Polly’s Run, a fundraiser to support pancreatic cancer research, will take place Sunday, June 3, at Tiguex Park near Albuquerque’s Old Town. The event will feature a 5K run/walk that starts at 8:30 a.m. and a Kid’s K that starts at 9:30 a.m. All proceeds benefit the Polly Rogers Pancreatic Cancer Research Fund at The University of New Mexico Comprehensive Cancer Center.